ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 03/03/2026

    Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck...

  • 02/26/2026

    Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

    CHICAGO, February 26, 2026 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a...

  • 02/24/2026

    Tempus Reports Fourth Quarter and Full Year 2025 Results

    CHICAGO, February 24, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics rev...

  • 02/18/2026

    Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to tra...

  • 02/12/2026

    Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support inform...

  • 02/10/2026

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chi...

  • 01/27/2026

    Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including...

  • 01/21/2026

    Tempus Announces the Launch of Paige Predict

    Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyz...

  • 01/12/2026

    Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

    Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s Center for Mo...

  • 01/12/2026

    Northwestern Medicine Selects Tempus to Expand Genomic Testing

    Collaboration will focus on the oncology patient population

    Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their uni...

1 2 3